Gruticibart Biosimilar - Research Grade

Human

F11

>1mg/ml

IgG4 - kappa

CHO Cells

Abelacimab Biosimilar - Research Grade (ICH5322), Osocimab Biosimilar - Research Grade (ICH5747)

https://www.imgt.org/mAb-DB/

ICH3002

P03951

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the originator anti-Factor XI antibody gruticibart, supplied for research use only. It is a full-length human IgG4-kappa immunoglobulin built around the coagulation Factor XI (F11, UniProt P03951) target, produced recombinantly and intended as a laboratory reagent rather than the clinical drug; it is not for human or veterinary use. The analog is useful for researchers studying the contact and intrinsic coagulation pathways, FXI/FXIa biology, and antibody-based anticoagulation mechanisms. Typical research applications include use as a binding and neutralization reference standard, a benchmarking control in FXI target-engagement and epitope-competition assays, a tool for characterizing FXI activation by Factor XIIa, and a comparator in preclinical assay development and biosimilarity workflows. It is offered as a low-endotoxin, research-grade preparation (research grade less than 1 EU/mg; ultra-low-endotoxin option less than 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support in-vitro screening, formulation, and method-development studies. No clone identity is implied; the material is defined by its target specificity and human IgG4-kappa framework. Factor XI (F11; UniProt P03951) is a plasma zymogen of the intrinsic coagulation pathway, circulating as a disulfide-linked homodimer bound to high-molecular-weight kininogen. Each subunit contains four apple domains (A1-A4) and a C-terminal serine protease domain. FXI is classically activated to FXIa by Factor XIIa during contact activation, and can also be activated by thrombin; the apple 2 (A2) domain participates in FXIIa-mediated activation. Activated FXIa cleaves Factor IX to propagate thrombin generation and amplify clot formation. Because FXI contributes more to pathological thrombosis than to normal hemostasis, it is a leading target for anticoagulants aiming to separate antithrombotic efficacy from bleeding risk. Loss-of-function reflects hemophilia C, generally a milder bleeding phenotype, underscoring the therapeutic rationale for FXI inhibition.

FXI, Plasma thromboplastin antecedent, PTA, Coagulation factor XI

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks